Fermentas

US patents awarded to University of California, Hospital for Sick Children, Thermo Fisher, Fujifilm, Abbott, and Novartis.

The deal is expected to bolster Thermo's capabilities in PCR and quantitative real-time PCR.

The acquisition will add reagents for nucleic acid and protein purification, restriction and modifying enzymes, and other life science research and diagnostic tools to Thermo's Analytical Technologies portfolio.

When considering Thermo's planned acquisition of molecular biology tool shop Fermentas, its acquisition earlier this year of Finnish PCR firm Finnzymes, and recent product launches, it appears as if the company plans to make a run at disease diagnostics, food testing, and other PCR-based testing markets.

Thomas Weisel Partners called Thermo Fisher's planned $260 million acquisition of Fermentas a "synergistic tuck-in deal" that "bolsters Thermo's capabilities in the high-growth PCR market."

Based in Ontario with principal operations in Lithuania, Fermentas offers reagents for nucleic acid and protein purification, restriction and modifying enzymes, and various PCR products.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.